<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dexrazoxane: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dexrazoxane: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Dexrazoxane: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9338" href="/d/html/9338.html" rel="external">see "Dexrazoxane: Drug information"</a> and <a class="drug drug_patient" data-topicid="11718" href="/d/html/11718.html" rel="external">see "Dexrazoxane: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F158533"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Totect [DSC];</li>
<li>Zinecard [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866557"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Zinecard</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1046979"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidote</span>;</li>
<li>
<span class="list-set-name">Cardioprotective Agent</span>;</li>
<li>
<span class="list-set-name">Chelating Agent</span>;</li>
<li>
<span class="list-set-name">Chemoprotectant Agent</span></li></ul></div>
<div class="block dop drugH1Div" id="F9645632"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fba7fc71-7995-461f-aec9-136de5872215">Anthracycline-induced cardiomyopathy; prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anthracycline-induced cardiomyopathy; prevention:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> The International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) has determined that it is reasonable for pediatric patients who will receive a cumulative doxorubicin dose of ≥250 mg/m<sup>2</sup> or equivalent anthracycline dose to receive dexrazoxane with each anthracycline dose. In patients receiving higher doses of anthracyclines the benefits of dexrazoxane treatment probably outweigh the risks of developing secondary malignancies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36174614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36174614'])">Ref</a></span>). Refer to individual protocols for when dexrazoxane is indicated and for dosing.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: Dose is dependent on anthracycline dose: 10:1 dose ratio of dexrazoxane:doxorubicin (eg, 300 mg/m<sup>2</sup> dexrazoxane:30 mg/m<sup>2</sup> doxorubicin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32154021','lexi-content-ref-20850381','lexi-content-ref-17003366','lexi-content-ref-20016537']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32154021','lexi-content-ref-20850381','lexi-content-ref-17003366','lexi-content-ref-20016537'])">Ref</a></span>). Based on experience in adults and using isotoxic doxorubicin equivalent doses, the following dexrazoxane dosing ratios (dexrazoxane:anthracycline) for additional anthracyclines has been suggested: for daunorubicin 5 to 10:1 dose ratio, mitoxantrone 40:1 dose ratio, and idarubicin 50:1 dose ratio (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34889355']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34889355'])">Ref</a></span>). <b>Note:</b> Cardiac monitoring should continue during dexrazoxane therapy; anthracycline/dexrazoxane should be discontinued in patients who develop a decline in left ventricular ejection fraction or clinical congestive heart failure.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51108908"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: <b>Note:</b> There are no pediatric-specific dosage adjustments in the manufacturer's labeling; however, based on adult information and some pediatric centers, the following has been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥40 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;40 mL/minute: Reduce dose to 50% of the usual dose, using a 5:1 dexrazoxane:doxorubicin ratio (eg, dexrazoxane 150 mg/m<sup>2</sup>:doxorubicin 30 mg/m<sup>2</sup>).</p></div>
<div class="block dohp drugH1Div" id="F51108909"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Data in pediatric patients is insufficient to provide recommendations; refer to protocol if available. Experience in adult patients suggests when doxorubicin dosage is reduced due to hyperbilirubinemia, a proportional reduction in dexrazoxane dosage is recommended (to maintain a 10:1 ratio of dexrazoxane:doxorubicin).</p></div>
<div class="block doa drugH1Div" id="F158535"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9338" href="/d/html/9338.html" rel="external">see "Dexrazoxane: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d22f7e25-2551-4591-be23-d6cc9e76170c">Prevention of doxorubicin cardiomyopathy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prevention of doxorubicin cardiomyopathy:</b>
<b>IV:</b> A 10:1 ratio of dexrazoxane:doxorubicin (dexrazoxane 500 mg/m<sup>2</sup>:doxorubicin 50 mg/m<sup>2</sup>). Do not administer doxorubicin before dexrazoxane. Doxorubicin must be administered within 30 minutes of the completion of the dexrazoxane infusion.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="193c457a-834d-41c6-aab5-8043dc6d813f">Treatment of anthracycline extravasation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Treatment of anthracycline extravasation:</b>
<b>IV:</b> 1,000 mg/m<sup>2</sup> on days 1 and 2 (maximum dose: 2,000 mg/day), followed by 500 mg/m<sup>2</sup> on day 3 (maximum dose: 1,000 mg/day); begin treatment as soon as possible, within 6 hours of extravasation.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991692"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥40 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;40 mL/minute:</p>
<p style="text-indent:-2em;margin-left:4em;">Prevention of cardiomyopathy: Reduce dose to 50% of the usual dose, using a 5:1 dexrazoxane:doxorubicin ratio (eg, dexrazoxane 250 mg/m<sup>2</sup>:doxorubicin 50 mg/m<sup>2</sup>)</p>
<p style="text-indent:-2em;margin-left:4em;">Anthracycline extravasation: Reduce dose to 50% of the usual dose; monitor for signs of hematologic toxicity.</p></div>
<div class="block doha drugH1Div" id="F50989005"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Prevention of cardiomyopathy:</b> Since doxorubicin dosage is reduced in hyperbilirubinemia, a proportional reduction in dexrazoxane dosage is recommended (to maintain a 10:1 ratio of dexrazoxane:doxorubicin)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Anthracycline extravasation:</b> Use in patients with hepatic impairment is not recommended; monitor liver function tests prior to each dose in patients with known hepatic function disorders; hepatic dysfunction (transaminase and bilirubin elevations) may occur, particularly with doses above 1,000 mg/m<sup>2</sup>.</p></div>
<div class="block adr drugH1Div" id="F158507"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Prevention of doxorubicin cardiomyopathy (reactions listed are those which were greater in the dexrazoxane arm in a comparison of chemotherapy plus dexrazoxane vs chemotherapy alone):</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Infection: Infection (23%), sepsis (17%)</p>
<p style="text-indent:-2em;margin-left:6em;">Local: Pain at injection site (12%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Fatigue (≤61%), malaise (≤61%), neurotoxicity (17%)</p>
<p style="text-indent:-2em;margin-left:6em;">Miscellaneous: Fever (34%)</p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Phlebitis (6%)</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Erythema of skin (≤5%), localized erythematous streaking (≤5%)</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Anthracycline extravasation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Vascular disease (15%)</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Alopecia (14%)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Diarrhea (11%), nausea (43%), vomiting (19%)</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Decreased neutrophils (61%; grade 3: 22%; grade 4: 24%), decreased platelet count (26%; grade 3: 21%), decreased white blood cell count (73%; grade 3: 25%; grade 4: 20%)</p>
<p style="text-indent:-2em;margin-left:6em;">Hepatic: Increased serum alanine aminotransferase (22%), increased serum aspartate aminotransferase (28%), increased serum bilirubin (11%)</p>
<p style="text-indent:-2em;margin-left:6em;">Infection: Infection (30%), postoperative infection (16%)</p>
<p style="text-indent:-2em;margin-left:6em;">Local: Discomfort at injection site (≤16%), pain at injection site (≤16%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Dizziness (11%), fatigue (13%)</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Musculoskeletal signs and symptoms (13%)</p>
<p style="text-indent:-2em;margin-left:6em;">Renal: Increased serum creatinine (14%)</p>
<p style="text-indent:-2em;margin-left:6em;">Miscellaneous: Fever (21%)</p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Cardiac disorder (5%), peripheral edema (10%)</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Decreased serum sodium (6%), increased lactate dehydrogenase (5%), increased serum calcium (7%)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Abdominal pain (6%), anorexia (5%), constipation (6%)</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Anemia (6%), febrile neutropenia (3%)</p>
<p style="text-indent:-2em;margin-left:6em;">Hepatic: Increased serum alkaline phosphatase (4%)</p>
<p style="text-indent:-2em;margin-left:6em;">Local: Injection site phlebitis (6%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Depression (8%), headache (6%), insomnia (5%)</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Cough (5%), dyspnea (8%), pneumonia (6%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined (all indications):</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Granulocytopenia, leukopenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (all indications): Hematologic &amp; oncologic: Second primary malignant neoplasm (including myelodysplastic syndrome, secondary acute myelocytic leukemia)</p></div>
<div class="block coi drugH1Div" id="F158520"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Totect: There are no contraindications listed in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Zinecard, generic products: Use with chemotherapy regimens that do not contain an anthracycline.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Known hypersensitivity to dexrazoxane or any component of the formulation; use as a chemotherapeutic agent.</p></div>
<div class="block war drugH1Div" id="F158504"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Dexrazoxane may cause mild myelosuppression (leukopenia, neutropenia, and thrombocytopenia); myelosuppression may be additive with concurrently administered chemotherapeutic agents. Neutropenic fever has been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardioprotection: Dexrazoxane does not completely eliminate the risk of anthracycline-induced cardiac toxicity; carefully monitor cardiac function (left ventricular ejection fraction [LVEF]) prior to and periodically during treatment, and assess the benefits of continued therapy versus risks of potentially irreversible cardiac damage. The American Society of Clinical Oncology guidelines for prevention and monitoring of cardiac dysfunction in survivors of adult cancers indicate that dexrazoxane may be considered to prevent cardiotoxicity in patients planning to receive high-dose anthracyclines (eg, doxorubicin ≥250 mg/m<sup>2</sup> or epirubicin ≥600 mg/m<sup>2</sup>) (ASCO [Armenian 2017]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions, including anaphylactic reaction, angioedema, skin reactions, bronchospasm, respiratory distress, hypotension, and loss of consciousness have been reported. Use with caution. Carefully consider prior to use in patients with a previous allergy to dexrazoxane products.</p>
<p style="text-indent:-2em;margin-left:4em;">• Secondary malignancies: Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) have been reported in pediatric patients and some adult patients receiving dexrazoxane in combination with chemotherapy. The International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) has determined that it is reasonable for pediatric patients who will receive a cumulative doxorubicin dose of ≥250 mg/m<sup>2</sup> or equivalent anthracycline dose to receive dexrazoxane with each anthracycline dose. In patients receiving higher doses of anthracyclines, the benefits of dexrazoxane treatment probably outweigh the risks of developing secondary malignancies (IGHG [de Baat 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Tumor response: When used for cardiomyopathy prevention in the treatment of metastatic breast cancer, dexrazoxane should only be used in patients who have received a cumulative doxorubicin dose of ≥300 mg/m<sup>2</sup> and are continuing treatment with doxorubicin. Dexrazoxane may interfere with the antitumor effect of chemotherapy when given concurrently at chemotherapy initiation. In a study of patients with metastatic breast cancer who received fluorouracil, doxorubicin, and cyclophosphamide (FAC) with or without dexrazoxane beginning at cycle 1, patients who received dexrazoxane experienced a lower response rate and shorter time to progression (compared to patients who did not receive dexrazoxane beginning at cycle 1).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration (extravasation): Do not use DMSO in patients receiving dexrazoxane for anthracycline extravasation; may diminish dexrazoxane efficacy. Dexrazoxane is not effective against the effects of vesicants other than anthracyclines; if other vesicants (eg, vinca alkaloids, mitomycin) were also infused through the same extravasated IV access, consider extravasation management for those agents as well.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878417"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Secondary malignant neoplasms (SMN) have been reported with dexrazoxane and razoxane (racemic mixture of which dexrazoxane is the S[+] enantiomer) use; a multicenter review of pediatric trials reported the incidence of SMN to be very rare; a single case was reported out of 533 pediatric patients evaluated throughout 5-year follow-up (Vrooman 2011). A long-term follow-up study followed survivors from 6 different doxorubicin-containing pediatric protocols, 5 of which randomized patients to doxorubicin treatment with or without dexrazoxane; the study included 1,308 patients, of which 784 received dexrazoxane for a median follow-up of 18.6 years. Results showed that dexrazoxane treatment did not adversely affect long-term mortality, event-free survival, or secondary malignancy when compared to patients that did not receive dexrazoxane (Chow 2022).</p></div>
<div class="block foc drugH1Div" id="F158514"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Totect: 500 mg (1 ea [DSC]) [pyrogen free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zinecard: 250 mg (1 ea [DSC]); 500 mg (1 ea [DSC]) [pyrogen free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg (1 ea [DSC]); 500 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg (1 ea); 500 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F158500"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323101"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Dexrazoxane HCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $276.35 - $329.11</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $174.00 - $658.21</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866558"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zinecard: 250 mg (1 ea)</p></div>
<div class="block admp drugH1Div" id="F52612517"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV:</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Anthracycline-induced cardiomyopathy; prevention:</b> Administer dexrazoxane prior to anthracycline administration. Refer to individual protocols for timing of anthracycline administration.</p>
<p style="text-indent:-2em;margin-left:4em;">Totect, Zinecard, dexrazoxane generic: Administer over 15 minutes; do <b>not</b> administer by IV push. Administer anthracycline within 30 minutes after completion of dexrazoxane infusion (do not administer anthracycline before dexrazoxane).</p>
<p style="text-indent:-2em;margin-left:4em;">Dexrazoxane generic formulation with diluent (sodium lactate) provided: Administer by slow IV push or rapid IV drip infusion. Administer anthracycline within 30 minutes after initiation of dexrazoxane infusion (do not administer anthracycline before dexrazoxane).</p></div>
<div class="block adm drugH1Div" id="F158517"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infusion rate depends on indication.</p>
<p style="text-indent:-2em;margin-left:4em;">Prevention of doxorubicin cardiomyopathy: Administer doxorubicin within 30 minutes after completion of the dexrazoxane infusion (do not administer doxorubicin before dexrazoxane).</p>
<p style="text-indent:-2em;margin-left:6em;">Totect, Zinecard: Infuse over 15 minutes; do <b>not</b> administer by IV push.</p>
<p style="text-indent:-2em;margin-left:6em;">Dexrazoxane generic formulation (Eugia): Administer by slow IV push or rapid drip infusion</p>
<p style="text-indent:-2em;margin-left:2em;">Treatment of anthracycline extravasation: Remove cooling (dry cold compresses) for at least 15 minutes before dexrazoxane infusion to allow sufficient blood flow to extravasation site. Administer dexrazoxane IV over 1 to 2 hours into a large vein in an extremity/area other than the extravasation site; administer solution at room temperature. Begin infusion as soon as possible, within 6 hours of extravasation and continue withholding cooling during infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22997449']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22997449'])">Ref</a></span>). Day 2 and 3 dexrazoxane doses should be administered at approximately the same time (±3 hours) as the dose on day 1. Dexrazoxane is for IV administration only; not for local infiltration into extravasation. Do not use DMSO in combination with dexrazoxane; may lessen efficacy.</p>
<p style="text-indent:-2em;margin-left:4em;">General extravasation management (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22997449']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22997449'])">Ref</a></span>): Stop vesicant infusion immediately and disconnect IV line (leave needle/cannula in place); gently aspirate extravasated solution from the IV line (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Apply dry cold compresses for 20 minutes 4 times daily for 1 to 2 days (withhold cooling for at least 15 minutes before and during dexrazoxane infusion).</p></div>
<div class="block hazard drugH1Div" id="F49130973"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block sts drugH1Div" id="F158529"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Preparation and storage are product, diluent, and/or indication specific; refer to individual product labeling for further details. Discard unused solutions.</p>
<p style="text-indent:-2em;margin-left:2em;">Totect: Store intact vials at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light. Reconstituted solution (10 mg/mL) is stable for 30 minutes (must be further diluted within 30 minutes). Solutions diluted for infusion (if not used immediately) are stable for 4 hours at room temperature or up to 12 hours refrigerated (2°C to 8°C [36°F to 46°F]). <b>Note:</b> The stability of the reconstituted solution (10 mg/mL) was changed from 2 hours to 30 minutes in the November 2018 Totect prescribing information.</p>
<p style="text-indent:-2em;margin-left:2em;">Zinecard: Store intact vials at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). When reconstituted with SWFI, the reconstituted solution is stable for 30 minutes at room temperature or 3 hours refrigerated at 2°C to 8°C (36°F to 46°F). Solutions diluted for infusion in LR are stable for 1 hour when stored at room temperature or 4 hours refrigerated.</p>
<p style="text-indent:-2em;margin-left:2em;">Dexrazoxane generic formulation (Eugia; to be reconstituted with 0.167 Molar sodium lactate): Store intact vials at 20°C to 25°C (68°F to 77°F). Reconstituted solutions and solutions diluted for infusion in NS or D5W are stable for 6 hours when stored at room temperature or refrigerated at 2°C to 8°C (36°F to 46°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Additional stability information: When studied as a 24-hour continuous infusion for the prevention of cardiomyopathy, solutions prepared with sodium lactate diluent and diluted to a final concentration of 0.1 or 0.5 mg/mL in D5W were found to retain ≥90% of their initial concentration when stored at room temperature (ambient light conditions) for ≤24 hours (Tetef 2001).</p></div>
<div class="block usep drugH1Div" id="F53566449"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Reduction of the incidence and severity of anthracycline-induced (ie, doxorubicin-induced) cardiotoxicity in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m<sup>2</sup> and will benefit from continuing doxorubicin therapy to maintain tumor control; not recommended for use with initial doxorubicin therapy (Totect; Zinecard: FDA approved in adults); treatment of extravasation resulting from intravenous anthracycline chemotherapy (Totect: FDA approved in adults); has also been used for prevention of anthracycline-induced cardiomyopathy associated with treatment of other malignancies when higher doses of anthracyclines are indicated.</p></div>
<div class="block mst drugH1Div" id="F158563"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Zinecard may be confused with Gemzar</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299160"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6219749"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethyl Sulfoxide: May diminish the therapeutic effect of Dexrazoxane.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): Dexrazoxane may diminish the therapeutic effect of DOXOrubicin (Conventional).  Management: Do not administer dexrazoxane for cardioprotection at the time of doxorubicin initiation. This recommendation does not apply to the use of dexrazoxane for other indications (eg, extravasation), or to the use of dexrazoxane later in treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49297816"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Evaluate pregnancy status prior to use in patients who could become pregnant. Patients who could become pregnant should use highly effective contraception to prevent pregnancy during treatment and for 6 months after the last dexrazoxane dose. Patients with partners who could become pregnant should use effective contraception during therapy and for 3 months after the last dexrazoxane dose.</p></div>
<div class="block pri drugH1Div" id="F158523"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and findings in animal reproduction studies, dexrazoxane may cause fetal harm if administered during pregnancy.</p></div>
<div class="block mopp drugH1Div" id="F53566409"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC with differential (frequent); liver function; serum creatinine; cardiac function (for adults: repeat monitoring at 400 mg/m<sup>2</sup>, 500 mg/m<sup>2</sup>, and with every 50 mg/m<sup>2</sup> of doxorubicin thereafter; refer to individual protocol for pediatric cardiac assessment recommendations); monitor site of extravasation.</p></div>
<div class="block pha drugH1Div" id="F158503"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Dexrazoxane is a derivative of ethylenediaminetetraacetic acid (EDTA); a potent intracellular chelating agent. As a cardioprotectant, dexrazoxane appears to be converted intracellularly to a ring-opened chelating agent that interferes with iron-mediated oxygen free radical generation thought to be responsible, in part, for anthracycline-induced cardiomyopathy. In the management of anthracycline extravasation, dexrazoxane may act by reversibly inhibiting topoisomerase II, protecting tissue from anthracycline cytotoxicity, thereby decreasing tissue damage.</p></div>
<div class="block phk drugH1Div" id="F158519"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Distributes to heart, liver, and kidneys; V<sub>d</sub>: Children: 0.96 L/kg; Adults: 22 to 25 L/m<sup>2</sup></p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: None</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hydrolyzed by dihydropyrimidine aminohydrolase and dihydroorotase</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 2.1 to 2.5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (42%)</p></div>
<div class="block phksp drugH1Div" id="F51221000"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Clearance is reduced in patients with renal function impairment. The mean AUC was 2-fold higher in patients with moderate (CrCl 30 to 50 mL/minute) to severe (CrCl &lt;30 mL/minute) renal impairment.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F158525"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Dexrazoxane chiron</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Cardioxane | Cyrdanax | Savene</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Cardioxane | Savene</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cardioxane</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Cardioxane</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ao nuo xian</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Cardioxane | Razoxane</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Cardioxane | Cyrdanax</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cardioxane | Cyrdanax | Savene</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Cardioxane</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Cardioxane</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Cardioxane | Savene</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cardioxane | Cyrdanax | Savene</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cardioxane | Savene</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cardioxane | Savene</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cardioxane | Savene</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Savene</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Cardioxane | Savene</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Savene</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cardioxane</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Cardioxane</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Cardioxane | Dexpexel | Isoflur | Zucordex</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Cardioxane</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Cardioxane</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Razox</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Cardioxane | Cyrdanax</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Dexrazoxane | Zinecard</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Cardioxane</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cardioxan | Cardioxane</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Savene</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Savene</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Cardioxane | Cyrdanax</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Cardioxane</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cardioxane</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.2020">
<a name="USP.2020"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexrazoxane-pediatric-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20484616">
<a name="20484616"></a>Brier ME, Gaylor SK, McGovren JP, et al. Pharmacokinetics of Dexrazoxane in Subjects With Impaired Kidney Function. <i>J Clin Pharmacol</i>. 2011;51(5):731-738.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexrazoxane-pediatric-drug-information/abstract-text/20484616/pubmed" id="20484616" target="_blank">20484616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34644414">
<a name="34644414"></a>Chow EJ, Aplenc R, Vrooman LM, et al. Late health outcomes after dexrazoxane treatment: a report from the Children's Oncology Group. <i>Cancer</i>. 2022;128(4):788-796. doi:10.1002/cncr.33974<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexrazoxane-pediatric-drug-information/abstract-text/34644414/pubmed" id="34644414" target="_blank">34644414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36174614">
<a name="36174614"></a>de Baat EC, van Dalen EC, Mulder RL, et al. Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. <i>Lancet Child Adolesc Health</i>. 2022;6(12):885-894. doi:10.1016/S2352-4642(22)00239-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexrazoxane-pediatric-drug-information/abstract-text/36174614/pubmed" id="36174614" target="_blank">36174614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dexrazoxane.1">
<a name="Dexrazoxane.1"></a>Dexrazoxane [prescribing information]. East Windsor, NJ: AuroMedics Pharma LLC; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dexrazoxane.2">
<a name="Dexrazoxane.2"></a>Dexrazoxane hydrochloride [prescribing information]. East Windsor, NJ: Eugia US LLC; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32154021">
<a name="32154021"></a>Kopp LM, Womer RB, Schwartz CL, et al. Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children's Oncology Group. <i>Cardiooncology</i>. 2019;5:15. doi:10.1186/s40959-019-0050-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexrazoxane-pediatric-drug-information/abstract-text/32154021/pubmed" id="32154021" target="_blank">32154021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22370326">
<a name="22370326"></a>Lipshultz SE, Miller TL, Scully RE, et al. Changes in Cardiac Biomarkers During Doxorubicin Treatment of Pediatric Patients With High-Risk Acute Lymphoblastic Leukemia: Associations With Long-Term Echocardiographic Outcomes. <i>J Clin Oncol</i>. 2012;30(10):1042-1049.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexrazoxane-pediatric-drug-information/abstract-text/22370326/pubmed" id="22370326" target="_blank">22370326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20850381">
<a name="20850381"></a>Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. <i>Lancet Oncol</i>. 2010;11(10):950-961. doi:10.1016/S1470-2045(10)70204-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexrazoxane-pediatric-drug-information/abstract-text/20850381/pubmed" id="20850381" target="_blank">20850381</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16423847">
<a name="16423847"></a>Marty M, Espié M, Llombart A, et al. Multicenter Randomized Phase III Study of the Cardioprotective Effect of Dexrazoxane (Cardioxane) in Advanced/Metastatic Breast Cancer Patients Treated With Anthracycline-Based Chemotherapy. <i>Ann Oncol</i>. 2006;17(4):614-622.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexrazoxane-pediatric-drug-information/abstract-text/16423847/pubmed" id="16423847" target="_blank">16423847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17003366">
<a name="17003366"></a>Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for Children With Acute Lymphoblastic Leukemia. <i>Blood</i>. 2007;109(3):896-904.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexrazoxane-pediatric-drug-information/abstract-text/17003366/pubmed" id="17003366" target="_blank">17003366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17185744">
<a name="17185744"></a>Mouridsen HT, Langer SW, Buter J, et al. Treatment of Anthracycline Extravasation With Savene (Dexrazoxane): Results From Two Prospective Clinical Multicentre Studies. <i>Ann Oncol</i>. 2007;18(3):546-550.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexrazoxane-pediatric-drug-information/abstract-text/17185744/pubmed" id="17185744" target="_blank">17185744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34889355">
<a name="34889355"></a>Narayan HK, Getz KD, Leger KJ. Minimizing cardiac toxicity in children with acute myeloid leukemia. <i>Hematology Am Soc Hematol Educ Program</i>. 2021;2021(1):368-375. doi:10.1182/hematology.2021000268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexrazoxane-pediatric-drug-information/abstract-text/34889355/pubmed" id="34889355" target="_blank">34889355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22997449">
<a name="22997449"></a>Pérez Fidalgo JA, García Fabregat L, Cervantes A, et al. Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines. <i>Ann Oncol</i>. 2012;23(suppl 7):167-173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexrazoxane-pediatric-drug-information/abstract-text/22997449/pubmed" id="22997449" target="_blank">22997449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20016537">
<a name="20016537"></a>Silverman LB, Stevenson KE, O'Brien JE, et al. Long-Term Results of Dana-Farber Cancer Institute ALL Consortium Protocols for Children With Newly Diagnosed Acute Lymphoblastic Leukemia (1985-2000). <i>Leukemia</i>. 2010;24(2):320-334.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexrazoxane-pediatric-drug-information/abstract-text/20016537/pubmed" id="20016537" target="_blank">20016537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11410492">
<a name="11410492"></a>Tetef ML, Synold TW, Chow W, et al,. Phase I Trial of 96-Hour Continuous Infusion of Dexrazoxane I Patients With Advanced Malignancies. <i>Clin Cancer Res</i>. 2001;7(6):1569-1576.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexrazoxane-pediatric-drug-information/abstract-text/11410492/pubmed" id="11410492" target="_blank">11410492</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Totect.1">
<a name="Totect.1"></a>Totect (dexrazoxane) [prescribing information]. Yardley, PA: Clinigen Inc; November 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2016">
<a name="HHS.2016"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8955656">
<a name="8955656"></a>Venturini M, Michelotti A, Del Mastro L, et al. Multicenter Randomized Controlled Clinical Trial to Evaluate Cardioprotection of Dexrazoxane versus No Cardioprotection in Women Receiving Epirubicin Chemotherapy for Advanced Breast Cancer. <i>J Clin Oncol.</i> 1996;14(12):3112-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexrazoxane-pediatric-drug-information/abstract-text/8955656/pubmed" id="8955656" target="_blank">8955656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21514146">
<a name="21514146"></a>Vrooman LM, Neuberg DS, Stevenson KE, et al. The Low Incidence of Secondary Acute Myelogenous Leukaemia in Children and Adolescents Treated With Dexrazoxane for Acute Lymphoblastic Leukaemia: A Report From the Dana-Farber Cancer Institute ALL Consortium. <i>Eur J Cancer</i>. 2011;47(9):1373-1379.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexrazoxane-pediatric-drug-information/abstract-text/21514146/pubmed" id="21514146" target="_blank">21514146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23676513">
<a name="23676513"></a>Zhang YP, Myers AL, Trinh VA, et al, Physical and chemical stability of reconstituted and diluted dexrazoxane infusion solutions. <i>J Oncol Pharm Pract</i>. 2014;20(1):58-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dexrazoxane-pediatric-drug-information/abstract-text/23676513/pubmed" id="23676513" target="_blank">23676513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zinecard.1">
<a name="Zinecard.1"></a>Zinecard (dexrazoxane) [prescribing information]. New York, NY: Pharmacia &amp; Upjohn Company; October 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zinecard.2">
<a name="Zinecard.2"></a>Zinecard (dexrazoxane) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; April 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 13216 Version 265.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
